Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 695.46

+2.0%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/27/2019 9:34:59 PM
	of 3557

Is Bayer real, or cautious.... "And Bayer is tuning down its optimism on eye blockbuster Eylea, too, guiding to mere high-single-digit growth for 2019 after about 20% growth in 2018. “We’re seeing a little bit of a softening of the growth trend on Eylea,” Oelrich said. “We’re getting some headwinds in a few markets in terms of use of alternatives [or] dilute use of our product.” The FDA previously rejected Bayer partner Regeneron’s application for a pre-filled syringe of Eylea, asking for a usability study. Once the pair works that out, as they now expect to in mid-2019, Eylea could get a boost, “but that’s a little later,” Oelrich said. There is also the potential launch of Novartis’ next-generation VEGF inhibitor brolucizumab. The drug previously showed it could match Eylea in visual gains in age-related macular degeneration and even showed superiority in some key secondary endpoints. The Novartis drug also has the additional benefit of less frequent dosing. The Swiss drugmaker has just completed the new drug application submissions in the EU and U.S., and CEO Vas Narasimhan on the company’s own fourth-quarter earnings call said the company used a priority review voucher to ensure a launch in 2019. In its report in January, pharma intelligence shop EvaluatePharma estimated brolucizumab could reach $1.38 billion by 2024 sales."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next